Developing a new treatment for lung damage from toxic chemicals.
Official title: An Agnostic, Host-Direct Survival Cure MCM for Pulmonary Toxicants.
Funded at Xfibra, INC. · NIH-11006363 · Data updated 2026-11-12
This study is testing a new treatment called XFB19 to help heal lung injuries from harmful chemicals, and it's designed to support both military members and everyday people who might be affected by toxic exposures.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Xfibra, INC. NIH-funded |
| Lab location | 1 site (Del Mar, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $999,601 |
| NIH project number | 1R44AI186862-01 |
| Project ID | NIH-11006363 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have experienced lung damage from chemical warfare agents or industrial toxicants, as well as those diagnosed with Acute Respiratory Distress Syndrome or Idiopathic Pulmonary Fibrosis.
✕Less likely to help
Patients with lung conditions unrelated to toxic exposures or those who do not have significant inflammatory or fibrotic lung diseases may not benefit from this research.
What this research studies
This research focuses on creating a novel medical countermeasure (MCM) called XFB19 to treat lung injuries caused by exposure to chemical warfare agents and industrial toxicants. The approach involves using a specific peptide that targets inflammation and fibrosis in the lungs, which are critical issues in conditions like Acute Respiratory Distress Syndrome (ARDS) and Idiopathic Pulmonary Fibrosis. The research aims to demonstrate the safety and effectiveness of XFB19 through pre-clinical studies, ultimately benefiting both military personnel and civilians affected by toxic exposures.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from severe lung injuries due to toxic exposures.
How similar studies have gone: While the approach of using targeted peptides for lung injury is innovative, similar strategies have shown promise in other contexts, indicating potential for success.
Where this research is happening
-
Xfibra, INC.
Del Mar, United States Active
Researchers
- Principal investigator: Buck, Martina — Xfibra, INC.
- Study coordinator: Buck, Martina
Related research
Other NIH-funded projects on the same topics.
-
First-in-class treatment for liver cirrhosis with portal hypertension
A new therapy called XFB19 aims to reduce liver inflammation and scarring in people with advanced liver disease and portal hypertension.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.